Sheep breeding represents an important economic source in many countries; however, anthelmintic resistance is an important limiting factor for sheep breeding development, due to its effects in animal performance. Monepantel is an active principle derived from an amino-acetonitrile class, with proven efficacy in the control of gastrointestinal parasites. However, the side effects associated to this treatment remain unknown. Thus, the aim of this study was to evaluate the effect of anthelmintic treatment with monepantel as well as evaluate the hepatic function, proteic and lipid metabolism, and antioxidant/oxidant levels in serum of naturally infected sheep with helminths. Sixteen naturally infected animals were used; all subjects had similar parasitic degree (determined by McMaster technique) on day 0. The animals were divided in two groups (A and B) with eight animals each. Group A did not receive any treatment (control group), while group B received a single dose of monepantel (2.5 mg/kg) on day 0 of the experiment. Fecal exams performed on days 4 and 8 post-treatment (PT) revealed a significant reduction (p < 0.05) in the number of eggs per gram of feces (EPG) in the group B where animals were treated with monepantel. On days 4 and 8 PT, seric reactive oxygen species (ROS) and superoxide dismutase (SOD) activity increased (p < 0.05), while the catalase (CAT) activity in serum decreased (p < 0.05) within the group B. Based on these results, we can conclude that monepantel is very likely to be a safe drug, effective in the control of helminths, and possesses direct effect on SOD activation in sheep.
Comparative Clinical Pathology – Springer Journals
Published: May 17, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud